You are here: Home » 2025 » August » Archives for 27th

Countdown For A Cure Awards $350,000 Grant to Minovia Therapeutics to Advance Groundbreaking Mitochondrial Biomarker Research

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) — Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics Ltd., a clinical–stage company pioneering mitochondrial transplantation technologies. The funding will support Minovia’s research proposal to develop novel mitochondrial blood–based biomarkers that quantify mitochondrial content, quality, and function, with the goal of establishing a standardized “MitoScore.”

In addition to developing mitochondrial augmentation and transplantation (MAT)–based therapies, Minovia has set dual goals: advancing biomarkers to measure mitochondrial health and using these biomarkers to compare mitochondrial scores in healthy individuals and patients with mitochondrial disease. By doing so, Minovia aims to provide tools for earlier diagnosis, better disease tracking, and more effective evaluation of therapies.

Mitochondrial dysfunction is a hallmark not only of rare genetic diseases but also of chronic and age–related conditions. Despite its central role in human health, impacting the brain, heart, muscles, metabolism, and immunity, there are no approved therapies or functional diagnostic tests for mitochondrial dysfunction. When mitochondria become damaged or stop working properly, cells fail to produce enough energy, triggering a ripple effect that undermines nearly every system in the body. Causes can range from genetics and aging to environmental toxins, infections, poor diet, chronic stress, and medications. Because dysfunction often hides behind seemingly unrelated symptoms, it is frequently misdiagnosed or missed entirely, earning its reputation as the “hidden root cause” of disease.

“We shouldn’t just be fixing disease; we should be funding the future of health and healing. Supporting Minovia’s biomarker work is a crucial step in advancing mitochondrial medicine to the forefront of healthcare, not only for patients living with rare mitochondrial diseases, but also for the millions worldwide facing conditions linked to mitochondrial dysfunction. As one of the most overlooked drivers of health and disease, mitochondrial dysfunction plays a central role in everything from neurodegeneration and chronic fatigue to aging and metabolic disorders. By addressing this profound unmet need, we have an opportunity to transform how medicine prevents, diagnoses, and treats disease at its root,” said Mitzi Solomon, Founder & President of Countdown For A Cure Foundation.

Dr. Noa Sher, Chief Scientific Officer of Minovia, commented: “We are grateful to Countdown For A Cure Foundation, whose support will be instrumental in advancing the development of blood–based functional mitochondrial biomarkers. These tools will enable the identification of patients most likely to benefit from our MAT technology, as well as support patient follow–up after treatment. Given how critical mitochondria are to human health, we envision a future where mitochondrial biomarker assessments are part of routine checkups for individuals of all ages.”

About Minovia Therapeutics

Founded in 2011, Minovia Therapeutics, chaired by John Cox, is a clinical–stage biotechnology company developing treatments to replace dead or defective mitochondria with healthy mitochondria, helping people with mitochondrial diseases and fighting aging. Its lead therapy, MNV–201, is already in clinical testing for Pearson Syndrome and Myelodysplastic Syndrome.

The company is recognized globally for leading the first clinical trials in mitochondrial transplantation and continues to pioneer innovative therapies and biomarker development to bring energy–based healing to patients worldwide. Beyond rare mitochondrial diseases, Minovia is expanding its applications to broader areas where mitochondrial dysfunction plays a central role, including neurodegeneration, chronic fatigue, aging, and metabolic disorders.

Based in Haifa, Israel, Minovia operates a GMP facility for mitochondrial drug substance and drug product manufacturing to support its clinical trials, and it is planning expansion into the United States.

For more information, visit www.minoviatx.com.

About Countdown For A Cure

Countdown For A Cure (CFAC) is a foundation dedicated to accelerating mitochondrial medicine. Founded in 2024 by Mitzi and Jeff Solomon, who experienced mitochondrial dysfunction and its effects on their family firsthand, CFAC partners with leading research institutions and patient advocacy groups to fund bold, high–impact science and provide critical support to families. As a smart charity, CFAC invests in next–generation solutions for preventing, diagnosing, treating, and ultimately curing diseases rooted in cellular energy dysfunction, while also advancing healthy aging and extending longevity.

CFAC envisions a future where mitochondrial medicine revolutionizes healthcare by extending healthspan, transforming lives, and bringing energy–based healing to the forefront of medicine. Mitochondrial dysfunction affects nearly every area of medicine, including the brain, heart, muscles, and metabolism, yet it remains one of the most overlooked drivers of disease.

That is why CFAC is committed to advancing science, bridging clinical care, raising awareness of mitochondrial health, and uniting a global community determined to make a tangible difference in the lives of those affected by conditions and diseases linked to mitochondrial dysfunction.

For more information, visit www.countdownforacure.org.

Contacts:

Countdown For A Cure
Mitzi Solomon, Founder and President
[email protected] | +1 (917) 715–2381

Jeff Solomon, Founder
[email protected] | +1 (404) 272–0959

Vivian Martin, Communications Associate
[email protected] | +1 (404) 754–3337


GLOBENEWSWIRE (Distribution ID 9519437)

WOOF Deadline: WOOF Investors with Losses in Excess of $100K Have Opportunity to Lead Petco Health and Wellness Company, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”), of the important August 29, 2025 lead plaintiff deadline.

So what: If you purchased Petco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Petco class action, go to https://rosenlegal.com/submit–form/?case_id=41009 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Petco’s pandemic–related tailwinds were unsustainable, as was its business model of selling primarily premium and/or high–grade pet food; (2) accordingly, the strength of Petco’s differentiated product strategy was overstated; (3) defendants downplayed the true scope and severity of the foregoing issues, the magnitude of changes needed to rectify those issues, and the likely negative impacts of their mitigation strategy on Petco’s comparable sales metric; (4) accordingly, defendants overstated Petco’s ability to deliver sustainable, profitable growth; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Petco class action, go to https://rosenlegal.com/submit–form/?case_id=41009 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519129)